~~<i id='62F6C985DB'><strike id='62F6C985DB'><tt id='62F6C985DB'><pre id='62F6C985DB'></pre></tt></strike></i>~~

Home» explore» knowledge

knowledge

author：fashion 2025-09-30 22:34:12 Page View：9537

Hiram Secrist (left), who has Duchenne muscular dystrophy, with his mother, Kristen Secrist (center), and his grandmother, Terrie Jordan. Courtesy Secrist family

In mid-July, Kristen Secrist hopped on a call with her 5-year-old son’s doctor, who had urgent news: The first gene therapy had been approved for Duchenne muscular dystrophy. Her son, Hiram, would be a perfect candidate — if, she added, they could get him dosed in time.

The treatment was approved only for 4- and 5-year-olds. Hiram turned 6 in three weeks.

“Oh, crap,” Secrist said to herself.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： In his State of the Union, Biden takes clear aim at 'Big Pharma'
Next article： New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

leisure time

United colonoscopy coverage change 'may cost lives,' doctors say

AdobeWhengastroenterologistslearnedinMarchthatUnitedHealthcareplanstobarricademanycolonoscopiesbehin

With psoriasis trial ahead, Alumis raises $259 million

Aclose-upofpsoriasisonahand.AdobeSanFranciscostartupAlumisInc.hasraised$259millioninabidtobestbigpha

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

FILE-Abortion-rightsprotestersfillIndianaStatehousecorridorsandcheeroutsidelegislativechambers,Frida

Prescription digital therapeutics are key to pharma’s future

AdobeFiveyearsfromnow,whenpatientswalkintoadoctor’sofficepresentingsymptomsofalmostanyconditionyouca